97 related articles for article (PubMed ID: 10955300)
1. [Glutamate receptor antagonists attenuate experimental catalepsy in rats].
Rukoiatkina NI; Gorbunova LV; Gmiro VE; Lukomskaia NIa
Ross Fiziol Zh Im I M Sechenova; 2000 Jun; 86(6):626-33. PubMed ID: 10955300
[TBL] [Abstract][Full Text] [Related]
2. The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals.
Rukoyatkina NI; Gorbunova LV; Gmiro VE; Lukomskaya NY
Neurosci Behav Physiol; 2003 Mar; 33(3):273-8. PubMed ID: 12762595
[TBL] [Abstract][Full Text] [Related]
3. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.
Hauber W; Andersen R
Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):486-90. PubMed ID: 8114947
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of the anticonvulsant activity of organic mono- and di-cations and their potential to inhibit NMDA and AMPA glutamate receptors].
Lukomskaia NIa; Rukoiatkina NI; Gorbunova LV; Gmiro VE; Bol'shakov KV; Magazanik LG
Ross Fiziol Zh Im I M Sechenova; 2002 Sep; 88(9):1161-71. PubMed ID: 12503423
[TBL] [Abstract][Full Text] [Related]
5. The involvement of glutamatergic transmission in the mechanism of movement disorders induced by reversive rotation of white mice.
Lukomskaya NY; Zhabko EP; Gmiro VE
Neurosci Behav Physiol; 2000; 30(5):543-6. PubMed ID: 11037145
[TBL] [Abstract][Full Text] [Related]
6. Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.
Melo LL; Santos P; Medeiros P; Mello RO; Ferrari EA; Brandão ML; Maisonnette SS; Francisco A; Coimbra NC
Brain Res; 2010 Aug; 1349():41-7. PubMed ID: 20558148
[TBL] [Abstract][Full Text] [Related]
7. Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy.
Sevak RJ; Koek W; France CP
Eur J Pharmacol; 2005 Jul; 517(1-2):64-7. PubMed ID: 15975572
[TBL] [Abstract][Full Text] [Related]
8. Glutamatergic neurotransmission in the inferior colliculus influences intrastriatal haloperidol-induced catalepsy.
Medeiros P; Viana MB; Barbosa-Silva RC; Tonelli LC; Melo-Thomas L
Behav Brain Res; 2014 Jul; 268():8-13. PubMed ID: 24667361
[TBL] [Abstract][Full Text] [Related]
9. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain.
Kaur S; Ozer H; Starr M
Eur J Pharmacol; 1997 Aug; 332(2):153-60. PubMed ID: 9286616
[TBL] [Abstract][Full Text] [Related]
10. State-dependent blockade of haloperidol-induced sensitization of catalepsy by MK-801.
Schmidt WJ; Tzschentke TM; Kretschmer BD
Eur J Neurosci; 1999 Sep; 11(9):3365-8. PubMed ID: 10510204
[TBL] [Abstract][Full Text] [Related]
11. The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization.
Riedinger K; Kulak A; Schmidt WJ; von Ameln-Mayerhofer A
Behav Brain Res; 2011 Mar; 218(1):194-9. PubMed ID: 21130808
[TBL] [Abstract][Full Text] [Related]
12. The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.
McAllister KH
Eur J Pharmacol; 1996 Oct; 314(3):307-11. PubMed ID: 8957251
[TBL] [Abstract][Full Text] [Related]
13. Voltage-dependent block of native AMPA receptor channels by dicationic compounds.
Tikhonov DB; Samoilova MV; Buldakova SL; Gmiro VE; Magazanik LG
Br J Pharmacol; 2000 Jan; 129(2):265-74. PubMed ID: 10694232
[TBL] [Abstract][Full Text] [Related]
14. [A comparative study of the central H-cholinergic-blocking and NMDA-blocking actions of MK-801, memantin, amantadine, pyrilen and IEM-1754 in experiments on intact rats].
Gmiro VE; Serdiuk SE
Eksp Klin Farmakol; 2000; 63(2):16-20. PubMed ID: 10834088
[TBL] [Abstract][Full Text] [Related]
15. Design of antagonists for NMDA and AMPA receptors.
Bolshakov KV; Kim KH; Potapjeva NN; Gmiro VE; Tikhonov DB; Usherwood PN; Mellor IR; Magazanik LG
Neuropharmacology; 2005 Aug; 49(2):144-55. PubMed ID: 15996563
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Pharmacological Potency and Safety of Glutamate Blocker IEM-1913 and Memantine.
Gmiro VE; Serdyuk SE; Veselkina OS
Bull Exp Biol Med; 2015 Nov; 160(1):68-71. PubMed ID: 26601831
[TBL] [Abstract][Full Text] [Related]
17. [Effects of blockade of ionotropic glutamate receptors on the development of pentylenetetrazole kindling in mice].
Lukomskaia NIa; Lavrent'eva VV; Starshinova LA; Zhabko EP; Gorbunova LV; Tikhonova TB; Gmiro VE; Magazanik LG
Ross Fiziol Zh Im I M Sechenova; 2005 Nov; 91(11):1241-51. PubMed ID: 16408633
[TBL] [Abstract][Full Text] [Related]
18. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M
Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with NMDA antagonist, CGP 37849, and sigma receptor agonists, SA4503 or DTG, decreases the neuroleptic-induced catalepsy in rats.
Skuza G
Pol J Pharmacol; 2000; 52(4):313-6. PubMed ID: 11345488
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the anticonvulsive activities of organic mono- and dications with their abilities to inhibit NMDA and AMPA glutamate receptors.
Lukomskaya NY; Rukoyatkina NI; Gorbunova LV; Gmiro VE; Bol'shakov KV; Magazanik LG
Neurosci Behav Physiol; 2004 Feb; 34(2):181-7. PubMed ID: 15115325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
